tbuckley/cabot-search huggingface dataset:
THU0622 Patient-centered aging biobanks - a survey on public perceptions and patient choice among rheumatology outpatients
Authors: JV Cordeiro, A Fernandes, CD Lopes, G Victorino, P Lobato Faria, MJ Cercas, JC Branco, FM Pimentel-Santos
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Biobanks for research (BBR) are organized repositories of biological materials and associated health information with enormous potential and value for scientific research. In consonance with increasing attention to healthy aging research, BBR specifically oriented to chronic diseases and aging populations have gathered heightened attention. Public perceptions and patient choices are key to design, develop and implement patient-centered BBR. Public awareness, education and involvement are confidence building and unequivocally lead to higher participation in scientific enterprises. <h3>Objectives</h3> To assess patient awareness, perception and choices regarding aging biobanking activities. <h3>Methods</h3> We developed and applied a standard anonymous questionnaire to rheumatology terciary outpatients, aged 50 or older, between March-October 2016. Demographic data and perceptions about biobanking were collected. Data analysis was performed using Stata 14® software. <h3>Results</h3> We obtained a total of 131 valid responses [age (min-max, 50–93), mean (64); sex ratio (M/F) (40/91, 44%), education years (min-max, 0–20), mean (8.5)]. 69% of respondents did not know the specific term "biobank" but 57% were aware about the possibility of donating their biological material for research purposes. Furthermore, 77% of respondents indicated they were willing to contribute with their biological material to BBR, stating they had no particular preference whether these infrastructures were of private or public nature. However, they expressed a clear preference for these to be based at scientific research institutes (50%), instead of hospitals (23%), universities (16%) or biotechnology companies (7%). Moreover, respondents highlighted diferent requirements for their participation with anonymity (31%) and confidentiality (27%) ranking as top priorities. Most importantly, a majority of respondents (70%) expressed their agreement with a biobank exclusively dedicated to the study of aging, considering that people of older ages have higher disease burdens and that such research infrastructures and practices expressed respect for the particular problems of the elderly (Figure). <h3>Conclusions</h3> Our study constitutes a comprehensive assessment of public perceptions and patient choices regarding biobanks for aging research purposes among rheumatology outpatients. Although awareness is still suboptimal, BBR are highly regarded health infrastructures with enormous potential for further patient-centered development. <h3>Disclosure of Interest</h3> None declared
AB0058 Level of vascular endothelial growth factor a and intima-media thickness in patients with rheumatoid arthritis and osteoarthritis
Authors: VO Omelchenko, EA Letyagina, MA Korolev
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Early development of atherosclerosis (AS) with higher mortality risk is observed in patients with rheumatoid arthritis (RA). Actually, this problem hasn9t been solved. That9s why researches devoted to finding of relationships between RA and AS is still of current interest. In RA pannus formation accompanied by the development of new blood vessels forms main clinical manifestation. Vascular endothelial growth factor A (VEGF-A) is a heparin-binding glycoprotein, that induces the growth of blood vessels and plays a role in differentiation of endothelial cells. The expression of VEGF-A increases when plaque developes. <h3>Objectives</h3> To determine the particular qualities of VEGF-A production in patients with RA and various atherosclerotic damage of vessels. <h3>Methods</h3> 67 Caucasian patients with RA (age - 52 yr., [38;59], DAS28 5,25 [5,5;6,4]) were included in our study. Patients had American College of Rheumatology (ACR)-defined RA (1987 classification criteria). 45 Europeoid patients with OA (56 yr., [50;63]) were in control group. All patients gave written informed consent before enrollment. Level of VEGF-A was determined by ELISA for quantitative detection of human VEGF-A (Bender MedSystem GmbH, Austria). Range of atherosclerotic damage was assessed by ultrasonography with measurement of carotid intima-media thickness (IMT). IMT measured was compared with normal values according to the age and sex classes: younger 40 yr - 0,7 mm, 40–50 yr - 0,8 mm, elder 50 yr - 0,9 mm for men; younger 45 yr - 0,7 mm, 45–60 yr - 0,8 mm, elder 60 yr - 0,9 mm for women. Results is presented as median and 25th/75th percentiles (Me [25th percentile; 75th percentile]. Descriptive statistics, non-parametric Mann-Whitney U-test, Kruskal – Wallis test were used for analysis of the results. <h3>Results</h3> No significant differences of IMT were found between groups with RA and OA. Abnormal IMT were observed in about half of patients (Table 1). The highest level of VEGF-A was in OA-group with stenosing plaque (p&lt;0,01). No significant differences were found between other OA-subgroup. In patients with RA the highest level of VEGF-A was observed in subgroup with abnormal IMT (p&lt;0,05), but not with pluques. Generally, VEGF-A production in patients with normal IMT was higher in RA-patients, but not sugnificially. <h3>Conclusions</h3> Regulation of VEGF-A production may play a role in earlier onset of atherosclerosis in patients with RA. <h3>Disclosure of Interest</h3> None declared
Genetic polymorphisms associated with the risk of concussion in 1056 college athletes: a multicentre prospective cohort study
Authors: Thomas Roland Terrell, Ruth Abramson, Jeffery T Barth, Ellen Bennett, Robert C Cantu, Richard Sloane, Daniel T Laskowitz, David M Erlanger, Douglas McKeag, Gregory Nichols, Verle Valentine, Leslie Galloway
Journal: British Journal of Sports Medicine (2017)

To evaluate the association of genetic polymorphisms APOE, APOE G-219T promoter, microtubule associated protein(MAPT)/tau exon 6 Ser53Pro, MAPT/tau Hist47Tyr, IL-6572 G/C and IL-6RAsp358Ala with the risk of concussion in college athletes.A 23-centre prospective cohort study of 1056 college athletes with genotyping was completed between August 2003 and December 2012. All athletes completed baseline medical and concussion questionnaires, and post-concussion data were collected for athletes with a documented concussion.The study cohort consisted of 1056 athletes of mean±SD age 19.7±1.5 years, 89.3% male, 59.4% Caucasian, 35.0% African-American, 5.6% other race. The athletes participated in American football, soccer, basketball, softball, men's wrestling and club rugby. A total of 133 (12.1% prevalence) concussions occurred during an average surveillance of 3 years per athlete. We observed a significant positive association between IL-6R CC (p=0.001) and a negative association between APOE4 (p=0.03) and the risk of concussion. Unadjusted and adjusted logistic regression analysis showed a significant association between IL-6R CC and concussion (OR 3.48; 95% CI 1.58 to 7.65; p=0.002) and between the APOE4 allele and concussion (OR 0.61; 95% CI 0.38 to 0.96; p=0.04), which persisted after adjustment for confounders.IL-6R CC was associated with a three times greater concussion risk and APOE4 with a 40% lower risk.
AB0891 High frequencies of cvd risk factors, obesity, metabolic syndrome, and vitamin deficiencies in a danish cohort of gout patients
Authors: O Slot
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Gout is associated with increased risk of Cardio-Vascular Disease and death. <h3>Objectives</h3> To measure the frequencies of a number of potentially modifiable CVD risk factors in gout patients. <h3>Methods</h3> Comorbidities and CVD risk factors were measured and registered in a cohort of 100 consecutive new crystal proven gout patients. <h3>Results</h3> 88 males (62.1±13.6 years) and 12 females (74.1±6.9 years) were included. See table for results. <h3>Conclusions</h3> Nephropathy, obesity, and dyslipidemia are known to correlate to hyperuricemia and gout. Reciprocally hyperuricemia and gout may lead to development of comorbidities, i.e. hypertension, CVD, and nephropathy. Almost half the patients in this study were obese emphasizing the correlation between hyperuricemia and gout and obesity. Weight reduction is beneficial for control of hyperuricemia and gout, and is an important lifestyle factor that may be addressed in the treatment of hyperuricemia. Metabolic Syndrome is characterized by abdominal obesity and at least two of the following criteria: hypertension, diabetes, hypertriglyceridemia, and low blood levels of high-density-lipoprotein. Metabolic Syndrome is associated with a two-fold risk of CVD and was present in 72% of the gout patients. High homocysteine levels are correlated to endothelial dysfunction and increased risk of CVD. In this study the majority of patients had levels of homocysteine in the upper normal range, and a quarter had hyper-homocysteinemia. Elevated homocysteine has previously been reported in gout correlated to impaired renal function, but hyper-homocysteinmia can also be induced by low blood levels of cobalamin, which was present in 16%, and low levels of folate, which was found in 26%. In addition, low folate has been associated with endothelial dysfunction and CVD independently of homocysteine. Low levels of 25(OH)-vitamin D3 were observed in nearly half of the gout patients and deficiency were found in 19%. Obesity is known to be associated with low levels of vitamin D. Negative correlation between uric acid and Vitamin D has though been reported after correction for weight. Uric acid suppresses 1-alpha hydroxylase leading to low levels of 1,25(OH)2-vitamin D3 which is correlated to dyslipidemia and Metabolic Syndrome. Urate Lowering Therapy has been shown to counteract suppression of 1-alpha hydroxylase. Due to the increased risk of CVD and death associated with gout and the high prevalence of comorbidities and CVD risk factors in gout patients - comprehensive evaluation, information, and treatment of reversible co-morbidities and risk factors is recommended to be a part of the clinical management of gout. <h3>Disclosure of Interest</h3> None declared
AB0638 Cardiac transplant in systemic sclerosis-associated cardiomyopathy: monocentric experience of 3 cases
Authors: J Lenaerts, J Lenaerts, R Westhovens, W Droogne, A Ciarka, J Van Cleemput, E De Langhe
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Cardiac involvement in systemic sclerosis (SSc) is a frequent complication, but end-stage cardiac failure remains uncommon and represents a poor prognosis. Heart-lung and lung transplant is an established treatment option for SSc-related pulmonary disease. Due to the limited published data, no recommendations exist for cardiac transplant in the context of SSc. <h3>Objectives</h3> We present our monocentric experience of 3 patients with SSc who underwent cardiac transplant for SSc-related end-stage heart disease (multiple hospitalisations due to failure of medical therapy and life-threatening complications). <h3>Results</h3> <i>Case 1</i> is a 59-year-old male with limited cutaneous SSc. Antinuclear antibody (ANA) was negative. He had vascular (digital ulcers) and cardiac (heart failure (left ventricular ejection fraction (LVEF) 20%, NYHA class IV)) involvement, without major gastrointestinal or pulmonary involvement (no interstitial lung disease (ILD) or pulmonary arterial hypertension (PAH: assessed by right heart catheterization (RHC))). He underwent a cardiac transplant at the age of 51, after a disease duration of 6 years. Post-transplantation immunosuppressant therapy consists of tacrolimus and mycophenolic acid, initially associated with methylprednisolon, which is the standard immunosuppression protocol at our institution. <i>Case 2</i> is a 55-year-old male with limited cutaneous SSc. ANA was positive, 1/320, speckled pattern, but no SSc-related autoantibody has been identified. He had gastrointestinal (upper gastrointestinal tract dysmotility), muscular (myositis) and cardiac (heart failure with secondary cardiac cirrhosis (LVEF 40%, NYHA class III)) involvement, without major pulmonary involvement (no ILD or PAH). He underwent a cardiac transplant at the age of 54, after a disease duration of 7 years. Standard immunosuppressants were initiated. <i>Case 3</i> is a 50-year-old male with diffuse cutaneous SSc. ANA was negative. He had vascular (digital ulcers), gastrointestinal (upper gastrointestinal tract dysmotility) and cardiac (heart failure with secondary cardiac cirrhosis (LVEF 40%, NYHA class III)) involvement, without major pulmonary involvement (no ILD or PAH). He underwent a cardiac transplant at the age of 49, after a disease duration of 4 years. Standard immunosuppressants were initiated. At present, 1,5 years (case 2 and 3) and 8 years (case 1) after transplant, the donor hearts are still functioning well. No other SSc-related organ manifestations have occurred. <h3>Conclusions</h3> We present 3 patients with SSc who successfully underwent cardiac transplant for SSc-related end-stage heart disease. None had other major SSc-related organ involvement. This supports the limited published data that cardiac transplant is feasible and can be considered in end-stage SSc-related cardiomyopathy. <h3>Disclosure of Interest</h3> None declared
FRI0465 Angles of sacrum inclination effect on radiologic imaging reading in spondyloarthritis (the antelope-desir study)
Authors: M Herbette, L Deloire, F Garrigues, L Gossec, A Simon, A Feydi, F de Bruin, M Reijnierse, D van der Heijde, D Loeuille, P Claudepierre, T Marhadour, A Saraux
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> To assess the impact of spinal angles on clinical and imaging features of suspicion of axial spondyloarthritis (axSpA). <h3>Methods</h3> The DESIR cohort is a prospective longitudinal cohort study of adults aged 18–50 with inflammatory back pain (IBP) ≥3 months, ≤3 years. Baseline lateral lumbar radiography of patients included in DESIR cohort were read by two central blinded fellow readers (and a rheumatologist spine specialist in case of discrepancy) for Sacral Horizontal Angle (SHA), Lumbosacral angle (LSA) and total Lordotic Angle (TLA) measures. On the basis of literature, patients were classified depending on whether they had TLA more or less than 50°, SHA more or less than 40° or LSA more or less than 15°. Associations between angles and baseline clinical variables, presence of X-Rays (New York) and MRI (ASAS and MORPHO proposal definition) sacroiliitis, presence of spinal signs of spondyloarthritis (mSASSS, BASRI-total, SPARCC scores), presence of spinal degenerative MRI signs on X-rays (yes or no) and MRI (presence of Modic abnormalities, Pfirrmann score, Canal stenosis, Extrusion, High intensity zone Facet osteoarthritis) according to central reading (two readers) and axSpA diagnostic confidence (according to local clinician9s confidence on a 0–10 visual analog scale) were assessed by univariate analysis using the chi-square test (or Fisher9s exact test where appropriate) and the Mann-Whitney test. Adjustment for multiple testing was performed according to Bonferroni method. <h3>Results</h3> Of 708 patients, data were available for 677, 675 and 672 for SHA, LSA and TLA, measures with a mean value of 39.2°, 14.5° and 51.5° respectively. Clinical features and diagnostic confidence did not differ between the SHA, LSA and TLA groups. More sacroiliitis imaging, according to ASAS (41.4% versus 32.0%) and MORPHO definition (48.6% versus 39.3%), were reported in TLA&lt;50° group but the differences did not reach statistical significance. Radiological scores were low with a mean value of 0.49 (±1.83), 0.30 (±0.78) and 4.9 (±9.0) for mSASSS, BASRI-total and SPARCC score, respectively, and no inter-group difference was found. In L5S1, more grade 3 and 4 Pfirrmann class and MODIC discopathy (types 1 and 2) were observed for SHA &lt;40°, and TLA &lt;50° (p&lt;0.001) whereas the difference did not reach the significance level for LSA&lt;15° (p=0.05) (table). <h3>Conclusions</h3> Lumbar spine morphology is not associated with any clinical variable, presence on X-Rays or MRI of spinal signs of spondyloarthritis or sacroiliitis. At the L5S1 level, a more horizontal SHA and a reduction of TLA is associated with more degenerative radiological lumbar spine manifestations. <h3>Disclosure of Interest</h3> None declared
Changes in F18-flurodeoxyglucose uptake on serial cardiac positron emission tomography and left ventricular ejection fraction in patients with cardiac sarcoidosis
Authors: Michael T. Osborne, Edward A. Hulten, Avinainder Singh, Alfonso H. Waller, Márcio Sommer Bittencourt, Garrick C. Stewart, Hicham Skali, Jon Hainer, Sharmila Dorbala, Marcelo F. Di Carli, Ron Blankstein
Journal: Circulation (2013)

Apresentado no Scientific Sessions and Resuscitation Science Symposium of the American Heart Association, realizado em 16-17 de novembro de 2013 em Dallas, TX.
Diabetes, Prediabetes, and Brain Volumes and Subclinical Cerebrovascular Disease on MRI: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS)
Authors: Andrea L.C. Schneider, Elizabeth Selvin, A. Richey Sharrett, Michael Griswold, Josef Coresh, Clifford R. Jack, David Knopman, Thomas Mosley, Rebecca F. Gottesman
Journal: Diabetes Care (2017)

OBJECTIVE To examine the associations of prediabetes, diabetes, and diabetes severity (as assessed by HbA1c and diabetes duration) with brain volumes and vascular pathology on brain MRI and to assess whether the associations of diabetes with brain volumes are mediated by brain vascular pathology. RESEARCH DESIGN AND METHODS Cross-sectional study of 1,713 participants in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS) (mean age 75 years, 60% female, 27% black, 30% prediabetes, and 35% diabetes) who underwent 3T brain MRI scans in 2011–2013. Participants were categorized by diabetes-HbA1c status as without diabetes (&amp;lt;5.7% [reference]), with prediabetes (5.7 to &amp;lt;6.5%), and with diabetes ([defined as prior diagnosis or HbA1c ≥6.5%] &amp;lt;7.0% vs. ≥7.0%), with further stratification by diabetes duration (&amp;lt;10 vs. ≥10 years). RESULTS In adjusted analyses, compared with participants without diabetes and HbA1c &amp;lt;5.7%, participants with prediabetes and those with diabetes and HbA1c &amp;lt;7.0% did not have significantly different brain volumes or vascular pathology (all P &amp;gt; 0.05), but those with diabetes and HbA1c ≥7.0% had smaller total brain volume (β −0.20 SDs, 95% CI −0.31, −0.09), smaller regional brain volumes (including frontal, temporal, occipital, and parietal lobes; deep gray matter; Alzheimer disease signature region; and hippocampus [all P &amp;lt; 0.05]), and increased burden of white matter hyperintensities (WMH) (P = 0.016). Among participants with diabetes, those with HbA1c ≥7.0% had smaller total and regional brain volumes and an increased burden of WMH (all P &amp;lt; 0.05) compared with those with HbA1c &amp;lt;7.0%. Similarly, participants with longer duration of diabetes (≥10 years) had smaller brain volumes and higher burden of lacunes (all P &amp;lt; 0.05) than those with a diabetes duration &amp;lt;10 years. We found no evidence for mediation by WMH in associations of diabetes with smaller brain volumes by structural equation models (all P &amp;gt; 0.05). CONCLUSIONS More-severe diabetes (defined by higher HbA1c and longer disease duration) but not prediabetes or less-severe diabetes was associated with smaller brain volumes and an increased burden of brain vascular pathology. No evidence was found that associations of diabetes with smaller brain volumes are mediated by brain vascular pathology, suggesting that other mechanisms may be responsible for these associations.
SAT0535 Impact of the metabolic syndrome on the prevalence, severity incidence and progression of knee osteoarthritis
Authors: N Oreiro-Villar, M Fernandez-Moreno, E Cortes-Pereira, ME Vazquez-Mosquera, S Relaño, S Pertega, C Fernandez-Lopez, FJ Blanco, I Rego-Perez
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The contribution of metabolic factors on the development of OA has not been fully elucidated. <h3>Objectives</h3> The aim of this work is to analyze the influence of metabolic syndrome in the rate of radiographic incidence and progression of knee osteoarthritis, as well as its impact on the prevalence and severity of the disease. <h3>Methods</h3> For this work we used data from the Spanish cohort PROCOAC (PROgnostic Cohort of OsteoArthritis A Coruña). This cohort consists of subjects that visited the Rheumatology consultations at different time points and comprises 984 subjects at baseline including radiographic knee and hip KL grade, radiographic hand OA status, demographic and clinical data as well as the necessary information to assess the metabolic syndrome at baseline, that is, abdominal circumference (in cm) in addition to at least two of the following parameters: triglycerides above 200mg/dL, low HDL (&lt;35 mg/dL), hypertension and increased glucose blood levels (&gt;110 mg/dL). To assess the severity of the disease, the number of affected joints was coded as 0–1 and 2–3, according to the radiographic information of hands, knees and hips. Appropriate statistical analyses including Cox regression models with Kaplan-Meier survival curves and chi-square contingency tables were performed with SPSS v19. <h3>Results</h3> The mean age of subjects was 63,86 [32–88] years; 75,6,% were women. A total of 85% had radiographic hand OA and 11,8% suffered metabolic syndrome at baseline. In those OA patients that experienced radiographic knee OA progression over time (any KL increase from KL≥2 at baseline) the metabolic syndrome appeared as a significant risk factor (HR=3.696;95CI:1.085–14.520;p-value=0.037) (Figure 1). Similarly, in those subjects that developed incident radiographic knee OA over time (a new-onset KL grade 2), the metabolic syndrome at baseline also appeared as a significant risk factor with an increased magnitude (HR=12.931;95CI:3.037–55.051;p-value&lt;0.001) (Figure 1). In addition, to have contralateral knee OA at baseline (HR=12.837;95CI:5.044 – 32.673;p-value &lt;0.001) as well as radiographic hand OA (HR=5.671;95CI:0.854–37.649;p-value=0.07) associates with an increased rate of incident knee OA too. In terms of prevalence and severity of the disease, the metabolic syndrome associates with an increased risk of knee OA (OR=1.865;95% CI=1.080–3.220;p=0.024) as well as with increased number of affected joints, though in a non-significant manner (OR=1.582;95% CI=0.916–2.733;p=0.098) <h3>Conclusions</h3> The alterations that underlie the metabolic syndrome condition the severity and prevalence of knee osteoarthritis, as well as the rate of incidence and progression of the disease <h3>Disclosure of Interest</h3> None declared